相关实验视频

Updated: Jun 24, 2025

Identifying PD-1/PD-L1 Inhibitors with Surface Plasmon Resonance Technology

Identifying PD-1/PD-L1 Inhibitors with Surface Plasmon Resonance Technology

Published on: May 2, 2025

作为PD-1/PD-L1对手的Chroman衍生物的设计,合成和生物评估

Luosen Wang¹, Jie Hou¹, Peng Cao¹

¹Jiangsu Key Laboratory of Drug Discovery for Metabolic Disease, State Key Laboratory of Natural Medicines, China Pharmaceutical University, Nanjing 210009, China.

Journal of chemical information and modeling

|June 10, 2024

概括

研究人员开发了新的小分子抑制剂,针对编程死亡配体1 (PD-L1) 来对抗癌症免疫逃避. 该化合物 (R) -C27表现出卓越的抑制活性,显示出进一步治疗发展的前景.

科学领域:

药用化学医学化学
免疫学免疫学免疫学
结构生物学结构生物学

背景情况:

编程死亡配体1 (PD-L1) 是瘤免疫逃避的关键媒介,也是瘤学中重要的治疗标.
开发PD-1/PD-L1相互作用的小分子抑制剂为恢复抗瘤免疫提供了一个有希望的策略.

研究的目的:

设计和合成PD-L1.1的新型类小分子抑制剂.
评估新型PD-L1抑制剂的抑制活性和结构基础,重点关注化合物C27.

主要方法:

合成类似于的小分子,利用"接近环"的策略来进行形状限制.
在体外生物测试以评估PD-1/PD-L1抑制活性.
分子动力学模拟和结合的自由能量计算.
用于结构阐明的X射线晶体学.

主要成果:

化合物C27表现出强大的PD-1/PD-L1相互作用的抑制,超过了积极对照.
计算预测表明, (R) -C27与其反体 (S) -C27.27相比具有更高的抑制活性.
实验生物测试和X射线结构分析证实了 (R) -C27.7的优越活性和结合方式.

结论:

新的状小分子 (R) -C27是开发新的癌症免疫疗法的非常有前途的化合物.
这项研究强调了"环闭"策略在设计强效PD-L1抑制剂中的有效性.
(R) -C27需要进一步研究其在癌症治疗中的治疗潜力.

更多相关视频

Functionalized Spirocyclic Heterocycle Synthesis and Cytotoxicity Assay

Functionalized Spirocyclic Heterocycle Synthesis and Cytotoxicity Assay

Published on: February 9, 2021

Development of a 68Gallium-Labeled D-Peptide PET Tracer for Imaging Programmed Death-Ligand 1 Expression

Development of a 68Gallium-Labeled D-Peptide PET Tracer for Imaging Programmed Death-Ligand 1 Expression

Published on: February 3, 2023

相关概念视频

Structure-Activity Relationships and Drug Design

Structure-Activity Relationships and Drug Design

Drug design is a dynamic field that involves discovering and developing new medications based on specific biological targets. This process heavily relies on structure-activity relationships (SAR) and quantitative structure-activity relationships (QSAR) to guide the design and optimization of efficient drugs.
SAR studies the intricate relationship between a drug's chemical structure and biological activity. It focuses on understanding how modifications to a drug's structure can influence...

Drug Discovery: Overview

Drug Discovery: Overview

Drug discovery is a multifaceted process involving extensive screening, testing, and optimization of lead compounds to identify potential new drugs for therapeutic use. It combines several approaches, including screening large numbers of natural products, chemical modification of known active molecules, identification of new drug targets, and rational design based on biological mechanisms and drug-receptor structure. These approaches are carried out in both academic research laboratories and...

Adrenergic Agonists: Chemistry and Structure-Activity Relationship

Adrenergic Agonists: Chemistry and Structure-Activity Relationship

Adrenergic agonists' structure-activity relationship (SAR) determines their selectivity and efficacy. These agonists comprise a phenylethylamine moiety with an aromatic ring and an ethylamine side chain.
Aromatic ring substitutions: Substituting the aromatic ring with –OH groups at positions 3 and 4 yields catecholamines (e.g., epinephrine), which have a high affinity for adrenoceptors. Hydrogen bonding between –OH groups and receptors enhances adrenergic activity.
Separation of...